Decision-making on pharmaceuticals within the European Commission has for many years been subject of ‘frame competition’ between health and industry. The unit responsible for pharmaceuticals was organised within DG Enterprise and Industry, and allegedly, it promoted the interests and concerns of the pharmaceutical industry. However, in March 2010 the unit was moved from DG Enterprise to DG Health and Consumer. In this paper, it is investigated to what extent and how this move has had any consequences for the work conducted by the unit. Applying an organisational perspective, it is argued that to some extent, it is possible to trace a change in the decision-making behaviour of the unit. This observation underlines the importance of DG structure for decision-making behaviour within the Commission. In a larger perspective, the findings in this case study contributes to the argument that a ‘normalisation’ of politics within the Commission is taking place.
